RFA-HL-23-006: Stimulating Access to Research in Residency (StARR) (R38)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 16, 2024.
From the official notice on Grants.gov, last changed January 20, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR38
- Funded byNHLBI, NIAID, NEI
- Median yearly award$346,073
- Typical project length5 years
- R38, Stimulating Access to Research in Residency. Research time for physicians and other clinicians during residency. Other open R38 notices.
Projects funded under RFA-HL-23-006 were run by National Heart Lung and Blood Institute (NHLBI, 21 projects), National Institute of Allergy and Infectious Diseases (NIAID, 10 projects), National Eye Institute (NEI, 3 projects) and National Institute on Aging (NIA, 2 projects), and 1 more. Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HL-23-006 in the NIH Guide.
Key dates
| Posted | January 19, 2022 |
|---|---|
| Deadline | May 16, 2024 |
| Archived by Grants.gov | June 21, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Most of the money in the 11 programs behind this notice (68% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this program is to recruit and retain outstanding, postdoctoral-level health professionals who have demonstrated potential and interest in pursuing careers as clinician-investigators. To address the growing need for this critical component of the research workforce, this funding opportunity seeks applications from institutional programs that can provide outstanding mentored research opportunities for Resident-Investigators and foster their ability to transition to individual career development research awards. The program will support institutions to provide support for up to 2 years of research conducted by Resident-Investigators in structured programs for clinician-investigators with defined program milestones. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Funded under RFA-HL-23-006 so far
NIH funded 38 projects under RFA-HL-23-006 in fiscal 2023 to 2026, at 31 institutions. The median yearly award was $346,073.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Utah Stimulating Access to Research in Residency | Utah State Higher Education System--University of Utah | 2026 | $231,044 |
| ROC StARR: Health and Immune Function Across the Lifespan | University of Rochester | 2026 | $478,129 |
| MGH Diseases of Aging Pathway Via Stimulating Access to Research in Residency (MGH DAP StARR) | Massachusetts General Hospital | 2026 | $268,680 |
| Emory R38 Research Training Program | Emory University | 2026 | $455,761 |
| Stimulating Access to Research in the University of Cincinnati Internal Medicine Residency Program | University of Cincinnati | 2026 | $237,124 |
| Medical College of Wisconsin Physician Scientist Immersion Program | Medical College of Wisconsin | 2026 | $191,864 |
| Mentored Research Training in Aging and Surgery (MERITAS) | Brigham and Women's Hospital | 2026 | $403,611 |
| UCSF Program in Resident Opportunities for Mentored Ophthalmic Training in Experimentation (PROMOTE) | University of California, San Francisco | 2026 | $252,573 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Other programs behind this notice
- Cancer Treatment Research
- Cancer Biology Research
- Cancer Centers Support Grants
- Cancer Detection and Diagnosis Research
- Cancer Research Manpower
- Cancer Control
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HL-23-006 still open?
No. It closed on May 16, 2024.
Who can apply for Stimulating Access to Research in Residency (StARR) (R38)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Stimulating Access to Research in Residency (StARR) (R38)?
Closed May 16, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-HL-23-006?
NIH RePORTER lists 38 projects funded under RFA-HL-23-006 in fiscal 2023 to 2026, at 31 institutions. The most were at Emory University, University of California, San Francisco, Stanford University.
Who has won Cancer Detection and Diagnosis Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, Fred Hutchinson Cancer Center, The Leland Stanford Junior University. The program made 1,944 awards worth $2.7 billion in that time.
Similar open grants
- Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)